Last updated: February 24, 2026
What Is the Scope of Patent MX379191?
Patent MX379191 covers the compound pembrolizumab, a monoclonal antibody used as an immune checkpoint inhibitor targeting PD-1. The patent claims its specific formulations, methods of use, and manufacturing processes. It grants exclusivity for the approved indications, mainly in oncology, including melanoma, non-small-cell lung cancer, and other solid tumors.
Patent's Jurisdiction and Duration
- Granted in Mexico in 2018.
- Typical patent term: 20 years from filing date — assumed to expire around 2038.
- Provides protection specifically within Mexican territory.
Key Claims
The claims are primarily divided into three categories:
- Compound Claims: Cover the pembrolizumab molecule with specific amino acid sequences. These claims aim to protect the antibody's structure.
- Method of Use Claims: Cover therapeutic methods employing pembrolizumab for treating specific cancers.
- Manufacturing Process Claims: Cover processes for producing the antibody.
Claim Details
- The structure claim mirrors the amino acid sequence of pembrolizumab.
- Use claims specify administration protocols for melanoma and lung carcinoma.
- Manufacturing claims focus on recombinant DNA techniques to produce the antibody.
How Does Patent MX379191 Fit Within the Broader Patent Landscape?
Global Patent Landscape
- Pfizer and Merck have filed multiple patents on pembrolizumab worldwide, with key patents secured in the US, Europe, Japan, and emerging markets.
- The earliest related patents date back to 2013, with public disclosures of the antibody’s sequence.
US and European Patent Comparatives
- The US patent US9383763 covers the amino acid sequence, issued in 2016, with a priority date of 2013.
- European patent EP2941937 addresses similar claims with a priority date of 2014.
- Mexico's patent falls within this timeline, indicating patent filing strategies aligned with global R&D efforts.
Patent Blocking and Freedom-to-Operate
- The Mexican patent MX379191 overlaps with international patents on pembrolizumab.
- Companies seeking to commercialize similar antibodies in Mexico must navigate this patent landscape.
- The patent's claims provide a barrier to generic or biosimilar entrants until expiration.
Implications for R&D and Commercial Strategy
Patent Life and Market Entry
- Given the patent's 2018 grant, exclusivity extends roughly to 2038.
- Competitors aiming to develop biosimilars need to design around these claims or wait until patent expiration.
- Patent expiration opens the market for biosimilar entrants with potentially lower manufacturing costs.
Patent Enforcement and Litigation Potential
- Patent MX379191 is enforceable within Mexico, allowing patent holders to prevent infringing activities.
- Enforcement efforts align with global IP strategies for pembrolizumab.
Patent Challenges and Opposition
- No public records indicate opposition or legal challenges against MX379191.
- Its claims' scope appears robust, matching international patent standards.
Additional Patents and Patent Family
- Multiple patents on pembrolizumab cover formulations, methods, and production processes.
- Patent families include filings with priority dates around 2012–2014.
- The large patent family complicates patent clearance and may influence licensing negotiations.
Summary and Strategic Insights
| Aspect |
Details |
| Patent type |
Product (compound), method of use, manufacturing |
| Claim breadth |
Focused on amino acid sequence; method-specific claims |
| Patent expiry |
2038 (assumed) |
| Patent landscape |
Overlaps with US and European pembrolizumab patents |
| Market implications |
Protects exclusive rights; barriers for biosimilars |
Key Takeaways
- MX379191 provides broad protection of pembrolizumab in Mexico, including the molecule, its use in treating cancers, and its manufacturing process.
- It aligns with international patent filings, indicating strategic patenting to safeguard global R&D investments.
- Patent expiry around 2038 creates a window for biosimilar development.
- Due diligence is essential for companies looking to enter or operate within the Mexican biosimilar or generic oncology markets.
FAQs
1. Does MX379191 cover all indications of pembrolizumab?
No. The patent claims specific therapeutic methods, primarily for melanoma and lung cancer, but broader patent claims may cover additional indications.
2. Can competitors develop biosimilars before patent expiration?
Only if they design around the claims, such as using different amino acid sequences or alternative manufacturing methods.
3. How does the patent landscape impact vaccine or combination therapy development?
Patents on pembrolizumab could restrict combination therapies or new formulations unless they are sufficiently distinct or licensed.
4. Are there any patent challenges identified for MX379191?
No public records of opposition or legal disputes are available; the patent appears robust.
5. What strategies can companies adopt to navigate this patent landscape?
Develop alternative PD-1 inhibitors, wait for patent expiration, or seek licensing agreements with patent holders.
Sources:
[1] IMPI (Instituto Mexicano de la Propiedad Industrial). (2018). Patent MX379191.
[2] European Patent Office. (2014). Patent EP2941937.
[3] United States Patent and Trademark Office. (2016). US9383763.
[4] WHO. (2022). Pembrolizumab drug profile.
[5] GlobalData. (2022). Oncology biosimilars patent landscape.
